Marjon Pasmooij

Head of Science Department at Medicines Evaluation Board (CBG/MEB) in April 2018 to Present

IRDiRC Therapies Scientific Committee member at IRDiRC (International Rare Diseases Research Consortium) in May 2021 to Present

Affiliate Associate Professor of Drug Regulatory Science at Utrecht University in November 2023 to Present

IRDiRC "N-of-1+ Therapies" Task Force Member at IRDiRC (International Rare Diseases Research Consortium) in March 2023 to May 2025

Member of Big Data Steering Group HMA-EMA at Medicines Evaluation Board (CBG/MEB) in May 2020 to July 2024

Chair of the IRDiRC Drug Repurposing Guidebook Task Force at IRDiRC (International Rare Diseases Research Consortium) in March 2022 to May 2023

Member of EU-Network Training Center Steering Group at Medicines Evaluation Board (CBG/MEB) in April 2018 to April 2023

Steering Group member of the Regulatory Science Network Netherlands at Regulatory Science Network Netherlands in May 2018 to February 2022

IRDiRC Chrysalis Project Task Force Member at IRDiRC (International Rare Diseases Research Consortium) in July 2020 to January 2022

Member of Big Data Task Force HMA-EMA at Medicines Evaluation Board (CBG/MEB) in March 2017 to June 2019

Principal Investigator, Department of Dermatology at University Medical Center Groningen in March 2010 to August 2018

Projectleader Patient-Focused Evaluation at Medicines Evaluation Board (CBG/MEB) in April 2014 to April 2018

Clinical assessor at Medicines Evaluation Board (CBG/MEB) in March 2008 to April 2018

Medical Writer at Medicines Evaluation Board (CBG/MEB) in October 2007 to February 2010

Postdoctoral Scholar at Stanford University in September 2006 to September 2007

PhD student, cum laude at University Medical Center Groningen in January 2002 to August 2006

PhD student, Department of Molecular Microbiology at University of Groningen in January 2001 to January 2002